Disappointing results from CORAL trial. (News).Teva Pharmaceutical Industries Teva Pharmaceutical Industries Ltd. (Hebrew: טבע תעשיות פרמצבטיות בע"מ), NASDAQ: TEVA is an international pharmaceutical company headquartered in , Ltd., of Petah Tikva, Israel, announced results from an interim analysis of the CORAL trial, an international, multi-center clinical trial of oral Copaxone (glatiramer acetate glatiramer acetate (glahtear´a-meer as´  tāt),n a medication used to decrease or stop a relapse of multiple sclerosis. ) in over 1,600 men and women with relapsing-remitting MS. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Teva, the interim analysis indicated that there was no statistically demonstrated benefit from either high or low doses of oral Copaxone compared with inactive placebo. At the recommendation of an independent data safety monitoring Safety Monitoring of a clinical trial is conducted by an independent physician with relevant expertise. This is accomplished by review of adverse event, immediately after they occur, with timely follow-up through resolution. committee, the study was continued until completion last fall so the full study data can be analyzed. This analysis will determine whether further clinical trials are warranted. |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion